India: DTAB Appoints Committee To Review Fixed Dose Combinations

Last Updated: 20 February 2018
Article by Sanjeev Kapoor and Saman Ahsan

Most Read Contributor in India, July 2019

The Drugs Technical Advisory Board (DTAB) has reportedly appointed an expert committee under Ms Nilima Shirsagar, retired dean of Mumbai's KEM Hospital to review the safety, efficacy and therapeutic justification of several fixed dose combinations (FDCs). Presently, it is unclear as to what would be the constitution of the said committee, and as to what would be the modus-operandi adopted by the said committee in reviewing these FDCs.


On 10 March 2016, the Central Government has issued 344 identically worded notifications (Notifications) prohibiting the manufacture, sale, and distribution of 344 fixed dose combinations. The Notifications purported to ban the FDCs in question, because they posed substantial risks to human life, and on ground that safer alternatives were available. The Notifications were purported to be based on the findings and recommendations of an expert committee (the Kokate Committee) appointed by the Central Government, which stated that the FDCs in question were found to have no 'therapeutic justification'. The Notifications were issued by the Central Government in exercise of its powers under Section 26A of the Drugs and Cosmetics Act, 1940 (Drugs Act). Five similar notifications were issued on 8 June 2017, whereby five FDCs were banned.

Judgement of the Delhi High Court

The Delhi High Court judgment set aside the Notifications issued by the Central Government. Although several issues were raised, the Delhi High Court set aside the notifications on only one moot point, i.e., the Notifications have been issued by the Central Government without consulting the DTAB and Drugs Consultative Committee (DCC), which were statutory bodies created under the Drugs Act, despite the Drugs Act mandated consultation. It is relevant to note that during the pendency of the petitions challenging the Notifications, vide its interim orders, the Delhi High Court has stayed the operation of the Notifications.

Challenge before the Supreme Court

On 15 December 2017, the Hon'ble Supreme Court pronounced its judgment in the FDC ban matters pursuant to an appeal filed by the Central Government against the judgment of the Hon'ble Delhi High Court dated 01 December 2016. The Hon'ble Supreme Court held that, Section 26A of the Drugs Act does not necessarily mandate any previous consultation with the DTAB. Thus, 'so long as the Central Government's satisfaction can be said to be based on relevant material, it is not possible to say that not having consulted the DTAB, the power exercised under the said Section would be non est.' Further, the civil appeal filed by the Central Government was disposed off in the following terms:

  1. FDCs manufactured pre 21 September 1988

    For certain FDCs that were manufactured pre 21 September 1988, the respective Notifications (1st March 2016) were set aside, as those cases were never meant to be referred to the Kokate Committee.
  2. FDCs which were post 21 September 1988, but were approved by DCG(I)

    The Supreme Court directed that all the FDCs that would fall under this category should be sent for re-examination to the DTAB.
  3. FDCs manufactured post 1988 and not approved by DCG(I)

    The Hon'ble Court proceeded to refer these FDCs to DTAB, so that it can examine each of these cases afresh, and ultimately send a report to the Central Government.

Mandate of the Committee appointed by DTAB

The Hon'ble Supreme Court proceeded to lay down the parameters that are required to be met by DTAB, and/or a Sub-Committee formed by the DTAB, when it re-examines the FDCs and sends its report to the Central Government. Firstly, as per the directions of the Supreme Court, the DTAB/Sub-Committee appointed is to hear not only the pharmaceutical companies before the Supreme Court, but also the All India Drugs Action Network (an association which strongly supported the judgement of the Delhi High Court and alleged severe irregularities in grant of licenses for manufacture/distribution/sale of these FDCs). The Supreme Court further directed that the DTAB/Sub-Committee would first satisfy itself that the FDC in question was likely to involve any one of the ingredients specified in Section 26A, i.e., (a) that the FDC was likely to involve any risk to human beings or animals; or (b) that the said FDC did not have the therapeutic value claimed or purported to be claimed for them; or (c) that such FDC contains ingredients in such quantity for which there is no therapeutic justification. Additionally, the Supreme Court directed that the DTAB/Sub-Committee would also apply its mind as to whether it is necessary or expedient, in the larger public interest, to regulate, restrict, or prohibit the manufacture, sale, or distribution of such FDCs. In doing so, the DTAB/Sub-Committee was mandated to clearly indicate in its report as to (i) why, according to it, any one of the three factors indicated above is attracted; (ii) post such satisfaction, that in the larger public interest, it is necessary or expedient to (a) regulate, (b) restrict, or (c) prohibit the manufacture, sale or distribution of such FDCs. The DTAB/Sub-Committee was also directed to indicate in its report as to why, in case it prohibits a particular FDC, restriction or regulation is not sufficient to control the manufacture and use of the FDC. Lastly, the Supreme Court directed DTAB to afford a hearing to all concerned, and complete the entire exercise of sending a consolidated report within a period of six months from the date on which the judgment was received by the DTAB.


The constitution of the Sub-Committee by DTAB has been a much-awaited development since the pronouncement of the judgement of the Supreme Court. Needless to say, in so far as merits of the FDCs is concerned, courts are unlikely to interfere with the findings of the DTAB/Sub-Committee (as may be adopted by the Central Government), particularly in exercise of their writ jurisdiction. However, with such detailed and exhaustive parameters being set out by the Supreme Court on the mandate, procedure and functioning of the DTAB/Sub-Committee, the slightest omission or variance from the directions of the Supreme Court could result in litigation with pharmaceutical companies challenging the decision taken by the DTAB/Sub-Committee citing non-compliance of the decision of the Supreme Court.

The content of this document do not necessarily reflect the views/position of Khaitan & Co but remain solely those of the author(s). For any further queries or follow up please contact Khaitan & Co at

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions